Research, news and information on the effectiveness of oral pre-exposure prophylaxis (PrEP) and its impact on HIV epidemics, as well as clinical issues for PrEP users.

PrEP science: latest news

PrEP science news from aidsmap

  • Another rare PrEP failure reported in San Francisco

    A San Francisco man was apparently infected with partially resistant HIV despite consistent use of Truvada pre-exposure prophylaxis (PrEP), according to a poster presented at IDWeek 2018, held last week in San Francisco. This is the sixth known case of ...

    09 October 2018 | Liz Highleyman
More news

PrEP science news selected from other sources

  • First U.S. Failure of Truvada as PrEP Is Reported at IDWeek

    A poster presentation at IDWeek, a yearly conference held by the Infectious Diseases Society of America, revealed that a 21-year-old Latinx man has acquired HIV despite consistently high adherence to pre-exposure prophylaxis (PrEP). This new report is unique for several reasons, primarily because this is the first known HIV seroconversion with verified adherence to PrEP in the U.S.

    07 October 2018 | The Body Pro
  • Making Clinical Trials of PrEP More Inclusive of Women, No Matter Their Pregnancy Status

    Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?

    01 October 2018 | The Body Pro
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.